Literature DB >> 92993

Soluble proteins in the human atherosclerotic plaque. With spectral reference to immunoglobulins, C3-complement component, alpha 1-antitrypsin and alpha 2-macroglobulin.

W Hollander, M A Colombo, B Kirkpatrick, J Paddock.   

Abstract

A number of soluble proteins contained in human aortic intimal tissue was extracted into buffered saline (pH 7.4) and identified and quantitated by immunoelectrophoresis and immunodiffusion. The proteins included IgA, IgG, IgM, B1C (C3), alpha 1-antitrypsin, alpha 2-macroglobulin, fibrinogen, albumin, LDL, HDL, alpha 1-acid glycoprotein, beta 2-glycoprotein, transferrin and ceruloplasmin. The concentration of soluble proteins was significantly higher in the atherosclerotic intima than in the normal intima. The diseased intima also contained a small amount of tissue-bound IgG, IgA and B1C which was extractable with citrate buffer at pH 3.2. The vascular band IgG, and B1C were shown by enzymatic and immunohistochemical studies to be closely associated with the collagenous tissue of the plaque. The Ig contained in the atherosclerotic plaque may be derived in part from the biosynthesis of Ig by the artery, since the incorporation of 14C-labeled leucine into IgG by the atheromatous plaque was demonstrable by radioimmunoelectrophoresis. In contrast to the diseased artery, the normal artery did not synthesize IgG and did not contain vascular bound IgG or complement. However, the normal artery was capable of fixing IgG and B1C eluted from the diseased artery. The present studies suggested that the IgG contained and synthesized by the plaque might represent an immune response to an endogenous or exogenous antigen closely associated with plaque collagen. IgG and B1C either alone or in the form of an immune complex also may play an important role in phagocytosis in the plaque and thereby influence the course of atherosclerosis. The proteolytic inhibitors, alpha 1-antitrypsin and alpha 2-macroglobulin, found in relatively high concentrations in the plaque, could enhance fibrosis of the lesion because of thier known inhibitory effects on collagenase and elastase.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 92993     DOI: 10.1016/0021-9150(79)90064-9

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  32 in total

1.  Identification of the prooxidant site of human ceruloplasmin: a model for oxidative damage by copper bound to protein surfaces.

Authors:  C K Mukhopadhyay; B Mazumder; P F Lindley; P L Fox
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

2.  Liver X receptor activation stimulates iron export in human alternative macrophages.

Authors:  Gaël Bories; Sophie Colin; Jonathan Vanhoutte; Bruno Derudas; Corinne Copin; Mélanie Fanchon; Mehdi Daoudi; Loïc Belloy; Stephan Haulon; Christophe Zawadzki; Brigitte Jude; Bart Staels; Giulia Chinetti-Gbaguidi
Journal:  Circ Res       Date:  2013-09-13       Impact factor: 17.367

3.  Low density lipoprotein undergoes oxidative modification in vivo.

Authors:  W Palinski; M E Rosenfeld; S Ylä-Herttuala; G C Gurtner; S S Socher; S W Butler; S Parthasarathy; T E Carew; D Steinberg; J L Witztum
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

4.  Role of endogenous ceruloplasmin in low density lipoprotein oxidation by human U937 monocytic cells.

Authors:  E Ehrenwald; P L Fox
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

5.  Plasma glycoproteins of diabetic and normal Chinese hamsters.

Authors:  J Copeland; K Blashfield; B Bauer; G C Gerritsen; L C Ginsberg
Journal:  Experientia       Date:  1982-03-15

Review 6.  High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosis.

Authors:  Scott M Gordon; Alan T Remaley
Journal:  Atherosclerosis       Date:  2016-11-16       Impact factor: 5.162

7.  Diagnostic and prognostic value of low density lipoprotein-containing circulating immune complexes in atherosclerosis.

Authors:  Igor A Sobenin; Vasily P Karagodin; Alexandra Capital A Cyrillic Melnichenko; Yuri V Bobryshev; Alexander N Orekhov
Journal:  J Clin Immunol       Date:  2012-10-17       Impact factor: 8.317

8.  Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atherosclerotic arteries.

Authors:  F Niculescu; F Hugo; H G Rus; R Vlaicu; S Bhakdi
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

9.  Diabetic dyslipidemia and exercise alter the plasma low-density lipoproteome in Yucatan pigs.

Authors:  Matthew R Richardson; Xianyin Lai; Joseph L Dixon; Michael Sturek; Frank A Witzmann
Journal:  Proteomics       Date:  2009-05       Impact factor: 3.984

10.  Anticomplement therapy.

Authors:  Prathit A Kulkarni; Vahid Afshar-Kharghan
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.